Sign In
Buy BIOVF
Swedish Orphan Biovitrum AB Earnings Calls
| Release date | Jul 16, 2026 |
| EPS estimate | $0.348 |
| EPS actual | $0.324 |
| EPS Surprise | -6.90% |
| Revenue estimate | 768.265M |
| Revenue actual | 809.184M |
| Revenue Surprise | 5.33% |
| Release date | Apr 28, 2026 |
| EPS estimate | $0.382 |
| EPS actual | $0.450 |
| EPS Surprise | 17.77% |
| Revenue estimate | 749.758M |
| Revenue actual | 755.757M |
| Revenue Surprise | 0.80% |
| Release date | Feb 05, 2026 |
| EPS estimate | $0.457 |
| EPS actual | $0.600 |
| EPS Surprise | 31.38% |
| Revenue estimate | 863.398M |
| Revenue actual | 846.232M |
| Revenue Surprise | -1.99% |
| Release date | Oct 20, 2025 |
| EPS estimate | $0.493 |
| EPS actual | $0.640 |
| EPS Surprise | 29.95% |
| Revenue estimate | 875.556M |
| Revenue actual | 823.478M |
| Revenue Surprise | -5.95% |
Last 4 Quarters for Swedish Orphan Biovitrum AB
Below you can see how BIOVF performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Oct 20, 2025 |
| Price on release | $33.30 |
| EPS estimate | $0.493 |
| EPS actual | $0.640 |
| EPS surprise | 29.95% |
| Date | Price |
|---|---|
| Oct 14, 2025 | $33.30 |
| Oct 15, 2025 | $33.30 |
| Oct 16, 2025 | $33.30 |
| Oct 17, 2025 | $32.06 |
| Oct 20, 2025 | $33.30 |
| Oct 21, 2025 | $33.30 |
| Oct 22, 2025 | $33.30 |
| Oct 23, 2025 | $33.30 |
| Oct 24, 2025 | $32.06 |
| 4 days before | 0% |
| 4 days after | -3.72% |
| On release day | 0% |
| Change in period | -3.72% |
| Release date | Feb 05, 2026 |
| Price on release | $41.55 |
| EPS estimate | $0.457 |
| EPS actual | $0.600 |
| EPS surprise | 31.38% |
| Date | Price |
|---|---|
| Jan 30, 2026 | $37.00 |
| Feb 02, 2026 | $37.00 |
| Feb 03, 2026 | $37.00 |
| Feb 04, 2026 | $37.00 |
| Feb 05, 2026 | $41.55 |
| Feb 06, 2026 | $41.55 |
| Feb 09, 2026 | $41.55 |
| Feb 10, 2026 | $41.55 |
| Feb 11, 2026 | $41.55 |
| 4 days before | 12.30% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 12.30% |
| Release date | Apr 28, 2026 |
| Price on release | $43.15 |
| EPS estimate | $0.382 |
| EPS actual | $0.450 |
| EPS surprise | 17.77% |
| Date | Price |
|---|---|
| Apr 22, 2026 | $39.87 |
| Apr 23, 2026 | $39.87 |
| Apr 24, 2026 | $39.87 |
| Apr 27, 2026 | $43.15 |
| Apr 28, 2026 | $43.15 |
| Apr 29, 2026 | $43.15 |
| Apr 30, 2026 | $43.15 |
| May 01, 2026 | $47.35 |
| May 04, 2026 | $47.35 |
| 4 days before | 8.23% |
| 4 days after | 9.73% |
| On release day | 0% |
| Change in period | 18.76% |
| Release date | Jul 16, 2026 |
| Price on release | $49.03 |
| EPS estimate | $0.348 |
| EPS actual | $0.324 |
| EPS surprise | -6.90% |
| Date | Price |
|---|---|
| Jul 10, 2026 | $49.03 |
| Jul 13, 2026 | $49.03 |
| Jul 14, 2026 | $49.03 |
| Jul 15, 2026 | $49.03 |
| Jul 16, 2026 | $49.03 |
| Jul 17, 2026 | $49.03 |
| Jul 20, 2026 | $49.03 |
| Jul 21, 2026 | $49.03 |
| Jul 22, 2026 | $49.03 |
| 4 days before | 0% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 0% |
Swedish Orphan Biovitrum AB Earnings Call Transcript Summary of Q2 2026
Sobi reported a very strong Q2 2026: revenue of ~SEK 7.8 billion (29% growth at constant currency) and an adjusted EBITA margin of 35%. Growth was broad-based across regions and driven by strategic portfolio products (notably ALTUVOCT, Doptelet, and Gamifant) and accelerating newer launches (Aspaveli). Management raised full-year guidance to mid-to-high teens revenue growth at CER and an adjusted EBITA margin in the mid-to-high 30s, reflecting H1 momentum. Key pipeline updates: positive REDUCE 2 Phase III topline results for pozdeutinurad (both 75 mg and 50 mg met the primary endpoint with strong urate reduction and favorable tolerability), advancement of Gamifant into a registrational Phase IIb/III program for interferon-γ–driven sepsis (EMBRACE II expected to start H2 2026 in Europe), and Tryngolza data showing meaningful reductions in triglycerides and acute pancreatitis risk in severe hypertriglyceridemia. NASP received an FDA Complete Response Letter related to CMC/manufacturing (no clinical safety/efficacy concerns); Sobi says the path to resubmission is clear and expects to resubmit within ~6–12 months. Financials show strong cash generation (operating cash flow SEK 1.9bn), net debt ~SEK 16bn (net debt/EBITA ~1.3x), and continued investment behind launches (higher SG&A and R&D in Q2). Management emphasized continued execution on launches, a diversified pipeline with multiple upcoming milestones (H2 2026 and into 2027), and confidence in reaching long-term revenue ambitions.
